Praxis Precision Medicines reported that its oral T‑type calcium channel inhibitor ulixacaltamide met primary and key secondary endpoints in two pivotal Phase 3 trials for essential tremor. The trials enrolled hundreds of patients across randomized and withdrawal cohorts; treated patients showed clinically meaningful improvement on activities‑of‑daily‑living scales and maintained effect during withdrawal phases. Praxis said it will pursue an NDA submission in early 2026 and highlighted robust patient interest and trial enrollment. Investors reacted strongly to the data, reflecting the size of the unmet need in essential tremor where no approved systemic therapy currently exists.